TransThera Sciences (Nanjing), Inc.

2617 · HKEX

Public Market Listing

2617HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for TransThera Sciences (Nanjing), Inc. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
Aurora A/B kinase (with secondary FGFR1/2/3, VEGFR1, JAK1/2, CSF1R inhibition)Small molecule
Breast CancerBiliary Tract Cancer
HR+/HER2- Metastatic Breast Cancer, Cholangiocarcinoma

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
TinengotinibPhase 3Cholangiocarcinoma
Est. primary completion 2026-12 · NCT05948475 · CT.gov ↗
What to watch
2027 (1)
June 2027 (1)
TinengotinibPhase 2Breast Cancer
Est. primary completion 2027-06-30 · NCT07498478 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
TinengotinibPhase 2Prostate Cancer (CRPC)
Est. primary completion 2028-12-31 · NCT07871110 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
TinengotinibPhase 3Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma
Est. primary completion 2029-12-31 · NCT07328919 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.